Literature DB >> 18752503

MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.

S O Yoon1, Y K Jeon, J H Paik, W Y Kim, Y A Kim, J E Kim, C W Kim.   

Abstract

AIMS: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with various genetic alterations. The aim was to investigate MYC, Bcl-2 and Bcl-6 translocations and copy number changes in adult DLBCLs to evaluate their clinicopathological features and prognostic implications. METHODS AND
RESULTS: Gene status was examined using fluorescence in situ hybridization (FISH), and the results were analysed in the context of germinal centre B-cell (GCB) and non-GCB type of DLBCL based on immunohistochemistry. MYC translocation was observed in 9% (14 of 156), and an increased copy number (ICN) in 7.1% (11 of 156). MYC translocation was more common in GCB type (22%) than in non-GCB type (4.9%), and associated with advanced International Prognostic Index (IPI). MYC aberration, i.e. translocation or increased copy number (ICN), was significantly associated with shorter overall survival, especially for the GCB type. Bcl-2 translocation was rare (3.4%, five of 145), and ICN was observed in 11.7% (17 of 145), more frequently in non-GCB type (16%) than in GCB type (2.5%). Bcl-2 aberration tended to have an adverse effect on survival. In multivariate analysis, MYC ICN was an independent poor prognostic factor.
CONCLUSIONS: Analyses of MYC and Bcl-2 status, i.e. translocation and ICN, in the context of DLBCL phenotype might help predict prognosis and determine therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752503     DOI: 10.1111/j.1365-2559.2008.03076.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  37 in total

1.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Parth A Desai; Pei Lin; Jason R Westin; Huda M Hawsawi; Peng Wei; Guilin Tang; Adam C Seegmiller; Nishitha M Reddy; C Cameron Yin; Wei Wang; Jie Xu; Roberto N Miranda; Zhuang Zuo; Shaoying Li
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Biology of double-hit B-cell lymphomas.

Authors:  R Coleman Lindsley; Ann S LaCasce
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

3.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Authors:  Mamta Gupta; Matthew J Maurer; Linda E Wellik; Mark E Law; Jing Jing Han; Nazan Ozsan; Ivana N Micallef; Ahmet Dogan; Thomas E Witzig
Journal:  Blood       Date:  2012-09-27       Impact factor: 22.113

Review 4.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

Review 5.  The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Authors:  Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Fabio Facchetti; Stefano Pileri; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-08-26       Impact factor: 4.064

6.  Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.

Authors:  Valentina Folgiero; Cristina Sorino; Matteo Pallocca; Francesca De Nicola; Frauke Goeman; Valentina Bertaina; Luisa Strocchio; Paolo Romania; Angela Pitisci; Simona Iezzi; Valeria Catena; Tiziana Bruno; Georgios Strimpakos; Claudio Passananti; Elisabetta Mattei; Giovanni Blandino; Franco Locatelli; Maurizio Fanciulli
Journal:  EMBO Rep       Date:  2018-01-24       Impact factor: 8.807

7.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

8.  Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Adam M Petrich; Benjamin A Chu; Amir Behdad; Shaoying Li; L Jeffrey Medeiros; Ryan D Cassaday; Nishitha M Reddy; Martin A Bast; Julie M Vose; Kimberly R Kruczek; Scott E Smith; Priyank Patel; Francisco Hernandez-Ilizaliturri; Reem Karmali; Saurabh Rajguru; David T Yang; Joseph J Maly; Kristie A Blum; Weiqiang Zhao; Charles Vanslambrouck; Chadi Nabhan
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

9.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma.

Authors:  Hong-Wei Zhang; Niu-Liang Cheng; Zhen-Wen Chen; Jin-Fen Wang; Su-Hong Li; Wei Bai
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.